In vitro susceptibility studies of Cryptococcus neoformans isolated from patients with no clinical response to amphotericin B therapy
The in vitro activities of three antifungal drugs alone and in combination were evaluated against five isolates of Cryptococcus neoformans using time-kill curves (TKC). The isolates were from AIDS patients who had either died or had failed to show a clinical response during amphotericin B (AMB) trea...
Gespeichert in:
| Veröffentlicht in: | Journal of antimicrobial chemotherapy 2000-02, Vol.45 (2), p.239-242 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 242 |
|---|---|
| container_issue | 2 |
| container_start_page | 239 |
| container_title | Journal of antimicrobial chemotherapy |
| container_volume | 45 |
| creator | RODERO, L CORDOBA, S CAHN, P HOCHENFELLNER, F DAVEL, G CANTEROS, C KAUFMAN, S GUELFAND, L |
| description | The in vitro activities of three antifungal drugs alone and in combination were evaluated against five isolates of Cryptococcus neoformans using time-kill curves (TKC). The isolates were from AIDS patients who had either died or had failed to show a clinical response during amphotericin B (AMB) treatment. AMB, fluconazole (FCZ) and flucytosine (5FC), and combinations of the drugs (AMB plus 5FC, AMB plus rifampicin (RIF) and FCZ plus 5FC), were evaluated. With all five isolates AMB did not show fungicidal activity; instead, a persistent or tolerant effect was observed. Combinations of AMB plus 5FC and AMB plus RIF showed a clear synergic effect, except for one isolate tested with AMB plus RIF. In contrast, the FCZ plus 5FC combination did not inhibit growth of any isolate. |
| doi_str_mv | 10.1093/jac/45.2.239 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_17561201</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>376617231</sourcerecordid><originalsourceid>FETCH-LOGICAL-c412t-7ffa29a347674b6cfabdee57405294e8ed29ee086e18ec6a3604493124ee0b23</originalsourceid><addsrcrecordid>eNpd0U2LFDEQBuAgiju7evMsQWRP9my-e_q4Dn4sLHjZe0inq5kM3UmbSivzA_zfRmZA8RQoHqpS9RLyhrMtZ528Ozp_p_RWbIXsnpENV4Y1gnX8OdkwyXTTKi2vyDXikTFmtNm9JFecGcM06zbk10OkP0LJieKKHpYS-jCFcqJY1iEA0jTSfT4tJfnk_Yo0QhpTnl1EGjBNrsBAx5xmurgSIBakP0M50Jion0IM3k00Ay4pItCSqJuXQyqQgw-RfqTlANktp1fkxegmhNeX94Y8ff70tP_aPH778rC_f2y84qI07Tg60TmpWtOq3vjR9QOAbhXTolOwg0F0AGxngO_AGycNU6qTXKha7YW8IbfntktO31fAYudQl54mV7da0fJWGy4Yr_Ddf_CY1hzr16zgdThXO1PRhzPyOSFmGO2Sw-zyyXJm_0RjazRWaStsjabyt5eeaz_D8A8-Z1HB-wtwWM82Zhd9wL9OSi25kr8BGSOZVg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>217671486</pqid></control><display><type>article</type><title>In vitro susceptibility studies of Cryptococcus neoformans isolated from patients with no clinical response to amphotericin B therapy</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Free Full-Text Journals in Chemistry</source><creator>RODERO, L ; CORDOBA, S ; CAHN, P ; HOCHENFELLNER, F ; DAVEL, G ; CANTEROS, C ; KAUFMAN, S ; GUELFAND, L</creator><creatorcontrib>RODERO, L ; CORDOBA, S ; CAHN, P ; HOCHENFELLNER, F ; DAVEL, G ; CANTEROS, C ; KAUFMAN, S ; GUELFAND, L</creatorcontrib><description>The in vitro activities of three antifungal drugs alone and in combination were evaluated against five isolates of Cryptococcus neoformans using time-kill curves (TKC). The isolates were from AIDS patients who had either died or had failed to show a clinical response during amphotericin B (AMB) treatment. AMB, fluconazole (FCZ) and flucytosine (5FC), and combinations of the drugs (AMB plus 5FC, AMB plus rifampicin (RIF) and FCZ plus 5FC), were evaluated. With all five isolates AMB did not show fungicidal activity; instead, a persistent or tolerant effect was observed. Combinations of AMB plus 5FC and AMB plus RIF showed a clear synergic effect, except for one isolate tested with AMB plus RIF. In contrast, the FCZ plus 5FC combination did not inhibit growth of any isolate.</description><identifier>ISSN: 0305-7453</identifier><identifier>EISSN: 1460-2091</identifier><identifier>DOI: 10.1093/jac/45.2.239</identifier><identifier>PMID: 10660509</identifier><identifier>CODEN: JACHDX</identifier><language>eng</language><publisher>Oxford: Oxford University Press</publisher><subject>Acquired Immunodeficiency Syndrome - microbiology ; amphotericin B ; Amphotericin B - pharmacology ; Amphotericin B - therapeutic use ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antifungal agents ; Antifungal Agents - pharmacology ; Antifungal Agents - therapeutic use ; Biological and medical sciences ; Cryptococcosis - microbiology ; Cryptococcus neoformans ; Cryptococcus neoformans - drug effects ; Drug Interactions ; Drug Resistance, Microbial ; fluconazole ; Fluconazole - pharmacology ; flucytosine ; Flucytosine - pharmacology ; Humans ; Leprostatic Agents - pharmacology ; Medical sciences ; Pharmacology. Drug treatments ; Rifampin - pharmacology ; Time Factors</subject><ispartof>Journal of antimicrobial chemotherapy, 2000-02, Vol.45 (2), p.239-242</ispartof><rights>2000 INIST-CNRS</rights><rights>Copyright Oxford University Press(England) Feb 2000</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c412t-7ffa29a347674b6cfabdee57405294e8ed29ee086e18ec6a3604493124ee0b23</citedby><cites>FETCH-LOGICAL-c412t-7ffa29a347674b6cfabdee57405294e8ed29ee086e18ec6a3604493124ee0b23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1335314$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10660509$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>RODERO, L</creatorcontrib><creatorcontrib>CORDOBA, S</creatorcontrib><creatorcontrib>CAHN, P</creatorcontrib><creatorcontrib>HOCHENFELLNER, F</creatorcontrib><creatorcontrib>DAVEL, G</creatorcontrib><creatorcontrib>CANTEROS, C</creatorcontrib><creatorcontrib>KAUFMAN, S</creatorcontrib><creatorcontrib>GUELFAND, L</creatorcontrib><title>In vitro susceptibility studies of Cryptococcus neoformans isolated from patients with no clinical response to amphotericin B therapy</title><title>Journal of antimicrobial chemotherapy</title><addtitle>J Antimicrob Chemother</addtitle><description>The in vitro activities of three antifungal drugs alone and in combination were evaluated against five isolates of Cryptococcus neoformans using time-kill curves (TKC). The isolates were from AIDS patients who had either died or had failed to show a clinical response during amphotericin B (AMB) treatment. AMB, fluconazole (FCZ) and flucytosine (5FC), and combinations of the drugs (AMB plus 5FC, AMB plus rifampicin (RIF) and FCZ plus 5FC), were evaluated. With all five isolates AMB did not show fungicidal activity; instead, a persistent or tolerant effect was observed. Combinations of AMB plus 5FC and AMB plus RIF showed a clear synergic effect, except for one isolate tested with AMB plus RIF. In contrast, the FCZ plus 5FC combination did not inhibit growth of any isolate.</description><subject>Acquired Immunodeficiency Syndrome - microbiology</subject><subject>amphotericin B</subject><subject>Amphotericin B - pharmacology</subject><subject>Amphotericin B - therapeutic use</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Antifungal agents</subject><subject>Antifungal Agents - pharmacology</subject><subject>Antifungal Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Cryptococcosis - microbiology</subject><subject>Cryptococcus neoformans</subject><subject>Cryptococcus neoformans - drug effects</subject><subject>Drug Interactions</subject><subject>Drug Resistance, Microbial</subject><subject>fluconazole</subject><subject>Fluconazole - pharmacology</subject><subject>flucytosine</subject><subject>Flucytosine - pharmacology</subject><subject>Humans</subject><subject>Leprostatic Agents - pharmacology</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><subject>Rifampin - pharmacology</subject><subject>Time Factors</subject><issn>0305-7453</issn><issn>1460-2091</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpd0U2LFDEQBuAgiju7evMsQWRP9my-e_q4Dn4sLHjZe0inq5kM3UmbSivzA_zfRmZA8RQoHqpS9RLyhrMtZ528Ozp_p_RWbIXsnpENV4Y1gnX8OdkwyXTTKi2vyDXikTFmtNm9JFecGcM06zbk10OkP0LJieKKHpYS-jCFcqJY1iEA0jTSfT4tJfnk_Yo0QhpTnl1EGjBNrsBAx5xmurgSIBakP0M50Jion0IM3k00Ay4pItCSqJuXQyqQgw-RfqTlANktp1fkxegmhNeX94Y8ff70tP_aPH778rC_f2y84qI07Tg60TmpWtOq3vjR9QOAbhXTolOwg0F0AGxngO_AGycNU6qTXKha7YW8IbfntktO31fAYudQl54mV7da0fJWGy4Yr_Ddf_CY1hzr16zgdThXO1PRhzPyOSFmGO2Sw-zyyXJm_0RjazRWaStsjabyt5eeaz_D8A8-Z1HB-wtwWM82Zhd9wL9OSi25kr8BGSOZVg</recordid><startdate>20000201</startdate><enddate>20000201</enddate><creator>RODERO, L</creator><creator>CORDOBA, S</creator><creator>CAHN, P</creator><creator>HOCHENFELLNER, F</creator><creator>DAVEL, G</creator><creator>CANTEROS, C</creator><creator>KAUFMAN, S</creator><creator>GUELFAND, L</creator><general>Oxford University Press</general><general>Oxford Publishing Limited (England)</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7QO</scope><scope>7T7</scope><scope>7U7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>P64</scope></search><sort><creationdate>20000201</creationdate><title>In vitro susceptibility studies of Cryptococcus neoformans isolated from patients with no clinical response to amphotericin B therapy</title><author>RODERO, L ; CORDOBA, S ; CAHN, P ; HOCHENFELLNER, F ; DAVEL, G ; CANTEROS, C ; KAUFMAN, S ; GUELFAND, L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c412t-7ffa29a347674b6cfabdee57405294e8ed29ee086e18ec6a3604493124ee0b23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Acquired Immunodeficiency Syndrome - microbiology</topic><topic>amphotericin B</topic><topic>Amphotericin B - pharmacology</topic><topic>Amphotericin B - therapeutic use</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Antifungal agents</topic><topic>Antifungal Agents - pharmacology</topic><topic>Antifungal Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Cryptococcosis - microbiology</topic><topic>Cryptococcus neoformans</topic><topic>Cryptococcus neoformans - drug effects</topic><topic>Drug Interactions</topic><topic>Drug Resistance, Microbial</topic><topic>fluconazole</topic><topic>Fluconazole - pharmacology</topic><topic>flucytosine</topic><topic>Flucytosine - pharmacology</topic><topic>Humans</topic><topic>Leprostatic Agents - pharmacology</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><topic>Rifampin - pharmacology</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>RODERO, L</creatorcontrib><creatorcontrib>CORDOBA, S</creatorcontrib><creatorcontrib>CAHN, P</creatorcontrib><creatorcontrib>HOCHENFELLNER, F</creatorcontrib><creatorcontrib>DAVEL, G</creatorcontrib><creatorcontrib>CANTEROS, C</creatorcontrib><creatorcontrib>KAUFMAN, S</creatorcontrib><creatorcontrib>GUELFAND, L</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>Journal of antimicrobial chemotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>RODERO, L</au><au>CORDOBA, S</au><au>CAHN, P</au><au>HOCHENFELLNER, F</au><au>DAVEL, G</au><au>CANTEROS, C</au><au>KAUFMAN, S</au><au>GUELFAND, L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>In vitro susceptibility studies of Cryptococcus neoformans isolated from patients with no clinical response to amphotericin B therapy</atitle><jtitle>Journal of antimicrobial chemotherapy</jtitle><addtitle>J Antimicrob Chemother</addtitle><date>2000-02-01</date><risdate>2000</risdate><volume>45</volume><issue>2</issue><spage>239</spage><epage>242</epage><pages>239-242</pages><issn>0305-7453</issn><eissn>1460-2091</eissn><coden>JACHDX</coden><abstract>The in vitro activities of three antifungal drugs alone and in combination were evaluated against five isolates of Cryptococcus neoformans using time-kill curves (TKC). The isolates were from AIDS patients who had either died or had failed to show a clinical response during amphotericin B (AMB) treatment. AMB, fluconazole (FCZ) and flucytosine (5FC), and combinations of the drugs (AMB plus 5FC, AMB plus rifampicin (RIF) and FCZ plus 5FC), were evaluated. With all five isolates AMB did not show fungicidal activity; instead, a persistent or tolerant effect was observed. Combinations of AMB plus 5FC and AMB plus RIF showed a clear synergic effect, except for one isolate tested with AMB plus RIF. In contrast, the FCZ plus 5FC combination did not inhibit growth of any isolate.</abstract><cop>Oxford</cop><pub>Oxford University Press</pub><pmid>10660509</pmid><doi>10.1093/jac/45.2.239</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0305-7453 |
| ispartof | Journal of antimicrobial chemotherapy, 2000-02, Vol.45 (2), p.239-242 |
| issn | 0305-7453 1460-2091 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_17561201 |
| source | Oxford University Press Journals All Titles (1996-Current); MEDLINE; EZB-FREE-00999 freely available EZB journals; Free Full-Text Journals in Chemistry |
| subjects | Acquired Immunodeficiency Syndrome - microbiology amphotericin B Amphotericin B - pharmacology Amphotericin B - therapeutic use Antibiotics. Antiinfectious agents. Antiparasitic agents Antifungal agents Antifungal Agents - pharmacology Antifungal Agents - therapeutic use Biological and medical sciences Cryptococcosis - microbiology Cryptococcus neoformans Cryptococcus neoformans - drug effects Drug Interactions Drug Resistance, Microbial fluconazole Fluconazole - pharmacology flucytosine Flucytosine - pharmacology Humans Leprostatic Agents - pharmacology Medical sciences Pharmacology. Drug treatments Rifampin - pharmacology Time Factors |
| title | In vitro susceptibility studies of Cryptococcus neoformans isolated from patients with no clinical response to amphotericin B therapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T13%3A17%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=In%20vitro%20susceptibility%20studies%20of%20Cryptococcus%20neoformans%20isolated%20from%20patients%20with%20no%20clinical%20response%20to%20amphotericin%20B%20therapy&rft.jtitle=Journal%20of%20antimicrobial%20chemotherapy&rft.au=RODERO,%20L&rft.date=2000-02-01&rft.volume=45&rft.issue=2&rft.spage=239&rft.epage=242&rft.pages=239-242&rft.issn=0305-7453&rft.eissn=1460-2091&rft.coden=JACHDX&rft_id=info:doi/10.1093/jac/45.2.239&rft_dat=%3Cproquest_cross%3E376617231%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=217671486&rft_id=info:pmid/10660509&rfr_iscdi=true |